{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T05:05:01Z","timestamp":1775883901875,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Venetoclax (Ven) and posaconazole (PSZ) are commonly co\u2010administered in patients with hematological diseases, including acute myeloid leukemia, chronic lymphocytic leukemia, and other related conditions. Due to CYP3A inhibition by PSZ, Ven plasma concentrations (ConcVen) are elevated, necessitating dose adjustments. This study aimed to quantitatively characterize the relationship between PSZ exposure and Ven pharmacokinetics through retrospective analysis of data from hematological patients receiving concurrent therapy. We examined correlations between ConcVen (both absolute and normalized by daily dose [ConcVen\/DD]) and PSZ exposure metrics (daily dose and plasma concentrations [ConcPSZ]) using Spearman's analysis. A population pharmacokinetic model incorporating an innovative rectified linear unit\u2010like function was developed to quantify the nonlinear interaction between these drugs and characterize Ven disposition, providing a more precise mathematical description of their relationship. This was followed by Monte Carlo simulations to predict steady\u2010state peak concentrations across various dosing scenarios and PSZ exposure concentrations. The analysis included 461 paired Ven\u2013PSZ concentration measurements from 282 patients. Significant correlations were observed between both ConcVen and ConcVen\/DD versus ConcPSZ (<jats:italic>P<\/jats:italic> &lt;\u00a0.01). Ven pharmacokinetics was best described by a two\u2010compartment model, with clearance showing significant concentration\u2010dependent reduction with increasing ConcPSZ. Simulations demonstrated that Ven doses of 70 and 100 mg daily maintained therapeutic steady\u2010state concentrations. However, careful monitoring of Ven concentrations is warranted when ConcPSZ exceeds 2.5 \u00b5g\/mL. Based on these findings, we recommend that Ven dose adjustments during concurrent PSZ therapy be guided by therapeutic drug monitoring of both agents, with dosing decisions informed by our population pharmacokinetic model incorporating measured ConcPSZ.<\/jats:p>","DOI":"10.1002\/jcph.70025","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T17:18:40Z","timestamp":1744478320000},"page":"1106-1115","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quantifying the Effect of Posaconazole on Venetoclax Metabolism in Chinese Patients With Hematologic Diseases"],"prefix":"10.1002","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9016-4723","authenticated-orcid":false,"given":"Wenli","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine Hebei Yanda Lu Daopei Hospital  Langfang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Hebei Yanda Lu Daopei Hospital  Langfang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"He","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplant Hebei Yanda Lu Daopei Hospital  Langfang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplant Hebei Yanda Lu Daopei Hospital  Langfang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Beijing Lu Daopei Hospital  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Hebei Yanda Lu Daopei Hospital  Langfang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xing","sequence":"additional","affiliation":[{"name":"Renascence Insurtech  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2808-7917","authenticated-orcid":false,"given":"Jian","family":"Cheng","sequence":"additional","affiliation":[{"name":"Renascence Insurtech  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Hebei Yanda Lu Daopei Hospital  Langfang China"},{"name":"Department of Laboratory Medicine Beijing Lu Daopei Hospital  Beijing China"},{"name":"Precision Medicine Center Beijing Lu Daopei Institute of Hematology  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"issue":"12","key":"e_1_2_10_2_1","first-page":"710","article-title":"Clinical practice guideline principles for treatment of hematologic malignancies with venetoclax (2021 edition)","volume":"30","author":"Leukemia Expert Committee of Chinese Society of Clinical Oncology (CSCO)","year":"2021","journal-title":"J Leuk Lymphoma"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26039"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6840"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30010-X"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2964"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2164610"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1137175"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.858"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13175"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.01.003"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04179-w"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-9927-9"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02170-w"},{"key":"e_1_2_10_17_1","volume-title":"Pharmacopoeia of People's Republic of China","author":"Committee National Pharmacopoeia","year":"2020"},{"key":"e_1_2_10_18_1","article-title":"Application number: 208573Orig1s000. Clinical pharmacology and biopharmaceutics review(s)","author":"Center for Drug Evaluation and Research","year":"2015","journal-title":"NDA"},{"issue":"5","key":"e_1_2_10_19_1","first-page":"321","article-title":"Expert consensus on clinical use of posaconazole (2022 edition)","volume":"15","author":"Danyang S","year":"2022","journal-title":"Chin J Clin Infect Dis"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.741"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.730"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0793-y"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-016-0485-9"},{"key":"e_1_2_10_24_1","volume-title":"Venclexta (Venetoclax) Tablets Full Prescribing Information","year":"2016"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2015.12.013"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112140\u201020240722\u201000500"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T07:00:30Z","timestamp":1756537230000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.70025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/jcph.70025"],"URL":"https:\/\/doi.org\/10.1002\/jcph.70025","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"assertion":[{"value":"2025-01-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}